Bio-Medical Devices for Pets PetVivo Holdings, Inc. (OTCQB: PETV)

Transcription

1 Bio-Medical Devices for Pets PetVivo Holdings, Inc. (OTCQB: PETV) Singletree Lane Suite 186 Eden Prairie, MN Website: Mark Bonacci Bio-Medical Devices for Pets

2 Analyst Credentials Mark Bonacci has been a long time trader on Wall Street and an executive at several companies in the private sector. Mr. Bonacci brings his experience as a CEO and stock trader to the Research Reports he writes. He has a degree in business administration. Contents Highlights.3 Fundamentals..3 Company Background.4 Products...4 Recent Events 5 Competition 6 Risk Factors.6 Analyst Summary 6 Ratings Guide 7 Disclaimer 7 Mark Bonacci Bio-Medical Devices for Pets

3 Market Data Market Capitalization (mln) $21 Fully Diluted Shrs Outstnd (mln) 3,779 Float (mln) 112 Ave. Volume (30 day mln) 2.8 Institutional Ownership N/A Insider Ownership 75% Exchange OTCQB Balance Sheet Data Shareholders Equity (000s) $1,042 ( ) Price / Book Value Net Cash (Debt mln) Working Capital (000s) Long-term Debt (000s) Revenue Data Total Revenue (000) N/A N/A Net Income (000) 95 (888) HIGHLIGHTS PetVivo Inc. is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. The company intends to leverage other company s investments in the human bio-materials and medical device industries to commercialize them for pets. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. The key to this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently scrutinized products for human use. According to the American Pet Products Association, total expenditures on pets, or animal companions, in the U.S. will exceed $58 billion this year with OTC medicine, supplies and veterinarian care accounting for $27.5 billion of that figure. In the U.S. 68% of households own a pet, with cats and dogs representing a vast majority of that figure. Farm animals such as horses and cows are not included in these figures but represent a very large market for bio-medical devices. Mark Bonacci Bio-Medical Devices for Pets

4 COMPANY BACKGROUND PetVivo, Inc. was a private company acquired by Technologies Scan Corp., already working toward the development of bio-medical devices for pets. On April 29, 2014, the Company s name changed from Technologies Scan Corp to PetVivo Holdings, Inc. The company changed its business model at the same time becoming an emerging company in the pet health market space through their subsidiary PetVivo, Inc. How much of the money spent at veterinarians is attributable to medical devices is unclear but PETV may have the opportunity to create market with its novel approach of introducing new products to veterinarians and pet owners. John Lai, CEO has been at PetVivo Holdings, Inc. since its inception. Mr. Lai has over 30 years of senior operations and financial experience, and has served as President, CFO, and Director, with a record of facilitating acquisitions, business launches, reverse mergers, and driving production revenue growth. PRODUCTS KUSH is the first of many veterinary therapeutic devices PetVivo, Inc. plans to commercialize. KUSH is a lubricious, cushion-like material that is injected into pet joints to augment synovial fluid function and treat joint dysfunction (lameness, osteoarthritis). The company anticipates that KUSH will be available to the veterinary therapeutic market in the fourth quarter of The company has been working with Dr. David Masters, CEO, inventor and founder of Gel-Del Technologies in St. Paul Minnesota, to bring veterinary device products to market under a license agreement, including Kush. CEO John Lai commented on KUSH, "We actually have a pretty good idea of our product pipeline in that we are planning to focus on devices rather than pharmaceuticals so that we can bring products to market faster without a formal FDA-approval process and provide veterinarians better products to treat their patients." The company states there are basically five distributors that handle over ninety percent of the veterinary products that are sold to veterinarians. They will market products to the various trade shows and to the distributors. Mark Bonacci Bio-Medical Devices for Pets

5 RECENT EVENTS Jul 23, 2014 (ACCESSWIRE via COMTEX) -- MINNEAPOLIS, MN. / ACCESSWIRE / PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics announced today that Gel-Del Technologies, Inc., the licensing and planned merger partner of PetVivo, has received a notice of allowance for issuance of their seventh US Patent. PetVivo and Gel-Del recently announced the signing of a binding term sheet to effect a merger and security exchange agreement between the companies. Gel-Del's intellectual property assets include proprietary coverage for medical devices/therapeutics and the coacervated/compressed biomimetic matrix materials used to make these products, including composition of material, manufacturing processes and methods of use, for both animals and humans. This newly allowed US patent application number 12/700,896 entitled "Protein Matrix Materials, Devices and Methods of Making and Using Thereof" secures the products and processes related to compressed matrix medical and drug delivery devices including applications involving tissue grafts, catheters, tissue replacement devices and wound care treatments. This allowed patent application is part of a worldwide intellectual property portfolio that secures Gel-Del's wide range of biomimetic materials and their applications. "We are very pleased with our recent success at the US Patent and Trademark Office wherein this government entity has recognized the uniqueness and broad inventiveness of our compressed and coacervated collagen matrix medical implant technologies," noted Gel-Del's CEO Dr. David B. Masters. "We continue to see the therapeutics benefits provided by Gel-Del's products in a broad range of implantable devices administered to a wide range of pets in addition to people. These successful therapies help demonstrate the value of Gel-Del's intellectual property portfolio." PetVivo CEO John Lai added, "In the near future, we look forward to launching our initial product Kush(TM) Canine, which has been demonstrated to improve joint function in dogs suffering from osteoarthritis. We truly believe these products will improve the quality of life of both pets and people." MINNEAPOLIS, MN, Jun 16, 2014 (Marketwired via COMTEX) -- PetVivo Holdings, Inc. (OTCQB: PETV), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics, is pleased to provide an update on the Kush study results for treating animal osteoarthritis. "We continue advancing our Kush device for the treatment of animal lameness," noted PetVivo CEO John Lai "I am excited about our Kush device, demonstrating great safety data for over eight years in five Mark Bonacci Bio-Medical Devices for Pets

6 species, including people. The case-study reports to treat bad joints in horses, started 3 years ago, and dogs, started 6 months ago, have been very positive." PetVivo has licensed the Kush device from Gel-Del Technologies, Inc. and is planning a launch in Q4 of this year. Gel-Del CEO Dr. David Masters reported, "Our Kush case-study observations are very encouraging, especially since to date we have only treated horses and dogs with severe osteoarthritis and lameness. These horses and dogs have all tolerated the particle joint injection treatments extremely well. In fact, after filling joint spaces in the lower limbs of horses and in the elbow and/or knee joints of dogs, we are seeing improved mobility and gait characteristics, and a reduction or elimination of pain meds in all animals treated. We are experiencing strong owner satisfaction that has resulted in additional Kush treatments to other afflicted joints in their pets." The two companies have previously announced that they have signed a term sheet to merge. Under the agreed upon terms Gel-Del will merge with PetVivo Holdings, Inc. and upon resolution of certain conditions specified as terms, a definitive agreement will consummate the merger. Dr. Masters noted, "I am looking forward to our merger so that we can address many unmet needs in veterinary and human patients." COMPETITION Pfizer (NYSE: PFE) and Novartis (NYSE: NVS) are each generating over a billion dollars in revenue from pet medications. In the pet market for osteoarthritis these companies are primarily focused on providing drugs to ease the pain associated with the disease, medications that would compete directly with PetVivo s KUSH product. Integra Lifesciences Holdings, Inc. (NASDAQ: IART) had revenue of $215 million in Q and is a manufacturer of veterinarian devices, mainly used for animal surgery. ANALYSTS SUMMARY PETV represents an investment in a potential market space with an undefinable upside. Humans spent a lot on their pets or animal companions with seemingly no limits. I don t know anyone that would let their pet suffer or be euthanized because the medical cost to make them Mark Bonacci Bio-Medical Devices for Pets

7 well was too much. People are not the only ones living longer; household pets are living longer as well. The quality of healthcare for pets is improving at a rate similar to humans. As these animals grow older they will be afflicted with the health issues similar to their human counterparts. The current price is attractive and the potential is virtually unlimited. RISK FACTORS The company is an emerging enterprise that has generated no revenue thus far. The market space for bio-medical devices for pets and other animals is largely unproven and undeveloped. PETV has issued most of its authorized shares and may have to raise that level to over its current level of 4 billion. DISCLAIMER Disclosure: I have no positions in any stocks mentioned. I wrote this article myself, it expresses my own opinions and is written in good faith. The compensation I receive is not related to the views and opinions expressed in this research report. I have no business relationship with any company whose stock is mentioned in the article. None of the information or opinions expressed constitutes a solicitation for the purchase or sale of any security. FORWARD-LOOKING DISCLAIMER This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forwardlooking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonacci, Analyst. An outsourced research services provider represented by Mark Bonacci, Analyst, provided Small Cap Specialists, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Specialists, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Mark Bonacci, Analyst. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapir.com. For any urgent concerns or inquiries, please contact us at admin@smallcapir.com. NO WARRANTY OR LIABILITY ASSUMED Mark Bonacci Bio-Medical Devices for Pets

8 Small Cap Specialists, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Specialists, LLC does not hold any positions in PETV. Small Cap Specialists, LLC has been previously compensated thirty five thousand dollars by Speak Easy Media, LLC for media coverage of PETV. No liability is accepted by Small Cap Specialists, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Specialists, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Specialists, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. Small Cap Specialists, LLC is the party responsible for hosting the full analyst report and Mark Bonacci, Analyst, is the author of research report. Small Cap Specialists, LLC has compensated Mark Bonacci, Chief Financial Analyst two hundred and fifty dollars for the right to disseminate this report. Information in this release is fact checked and produced on a best efforts basis by Mark Bonacci, Analyst. Mark Bonacci Bio-Medical Devices for Pets